Pettyjohn Wood & White Inc. Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Pettyjohn Wood & White Inc. trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,464 shares of the biopharmaceutical company’s stock after selling 328 shares during the period. Pettyjohn Wood & White Inc.’s holdings in Bristol-Myers Squibb were worth $366,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of BMY. Argyle Capital Management LLC raised its stake in Bristol-Myers Squibb by 3.9% during the 4th quarter. Argyle Capital Management LLC now owns 67,367 shares of the biopharmaceutical company’s stock valued at $3,810,000 after purchasing an additional 2,550 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of Bristol-Myers Squibb by 13.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 17,506 shares of the biopharmaceutical company’s stock worth $990,000 after buying an additional 2,030 shares in the last quarter. Wakefield Asset Management LLLP bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $3,406,000. QRG Capital Management Inc. increased its holdings in Bristol-Myers Squibb by 7.0% in the 4th quarter. QRG Capital Management Inc. now owns 309,565 shares of the biopharmaceutical company’s stock valued at $17,509,000 after acquiring an additional 20,177 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $13,593,000. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Trading Up 2.4 %

Bristol-Myers Squibb stock opened at $58.78 on Friday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market cap of $119.27 billion, a PE ratio of -13.30, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45. The stock has a 50-day moving average of $57.11 and a two-hundred day moving average of $54.61. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.22%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Bank of America reaffirmed a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price target for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Finally, Morgan Stanley increased their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.